Moderna (NasdaqGS:MRNA) Up 11% Despite Patent Lawsuit Challenges

Moderna (NasdaqGS:MRNA) saw an 11% increase in share price over the last week, likely influenced by recent legal and financial developments. The announcement of multiple international lawsuits from Genevant Sciences and Arbutus Biopharma over patent issues may have injected uncertainty, but the stock's rise could suggest investor confidence in Moderna's ability to navigate these challenges. The company's financial performance update, with significant declines in both quarterly revenue and earnings, contrasts with the market environment where major indices like the Nasdaq experienced sharp losses recently, with a market drop of 3.7% in the last week. In a broad market context, however, the encouraging CPI inflation report highlighted a potential slowdown in inflation, which helped boost the tech-heavy Nasdaq and may have contributed to Moderna's gain, as investors generally showed a renewed interest in tech and biotech stocks.

Our valuation report unveils the possibility Moderna's shares may be trading at a premium.

Searching for a Fresh Perspective? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Over the past five years, Moderna’s total shareholder return was 19.80%. During this period, the company faced significant legal and financial hurdles. Notably, multiple lawsuits related to patent infringements were filed against Moderna by Genevant Sciences and Arbutus Biopharma, posing potential risks. Additionally, the company experienced financial volatility with its Q4 2025 revenue dropping to US$966 million compared to US$2.8 billion the previous year, and a net loss of US$1.12 billion for the quarter. Despite its revenue forecast of 17.6% annual growth, challenges remain as the company is forecast to remain unprofitable over the next three years. Meanwhile, its Price-To-Sales Ratio indicates it is undervalued relative to the US Biotechs industry average.

Moderna’s expansions into mRNA production facilities, such as those in Kenya and Laval, Quebec, along with vaccine development such as its RSV mRNA vaccine, demonstrate growth ambitions. Recently, Health Canada's approval of mRESVIA™ for preventing respiratory diseases in older adults highlights product innovation. Furthermore, executive changes, including the appointment of Abbas Hussain to the Board, signal shifts in corporate governance aimed at navigating future challenges. Despite underperforming the US Biotechs industry over the past year, Moderna's commitment to advancing mRNA technology keeps it a key player in the biotech space.

Is Moderna part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com